How to Get Addyi in District of Columbia

What Flibanserin Is and Why DC Patients Seek It

Flibanserin is the only FDA-approved non-hormonal medication for hypoactive sexual desire disorder in premenopausal women. The FDA granted approval in August 2015 after a third review cycle. HSDD affects an estimated 8 to 10 percent of adult women in the United States, making it one of the most common female sexual dysfunctions recognized by the DSM-5 [1].

The drug works centrally. Flibanserin acts as a serotonin 1A agonist and serotonin 2A antagonist while also producing partial agonism at dopamine D4 receptors [2]. That receptor profile distinguishes it from all hormonal options, which is why it remains the preferred pharmacologic option for women whose desire disturbance is not driven by estrogen deficiency or androgen insufficiency.

Washington DC patients increasingly request flibanserin through telehealth channels because the District permits synchronous audiovisual visits to satisfy the prescriber-patient relationship requirement for controlled substances and REMS-regulated drugs. A 2023 survey published in the Journal of Women's Health found that 61 percent of women who discussed HSDD with a clinician reported doing so via telehealth for the first time [3]. DC's regulatory environment means those patients face no additional state-level barrier beyond the federal REMS program itself.

The Endocrine Society's 2019 Female Sexual Dysfunction guideline recommends offering flibanserin to premenopausal women with generalized, acquired HSDD after ruling out relationship factors, medication side effects, and mood disorders as primary causes [4]. That guideline sequence matters for documentation, because DC Medicaid and most commercial payers require chart evidence that alternative explanations have been addressed before authorizing flibanserin.

The DC Telehealth Prescribing Process Step by Step

DC telehealth providers can prescribe flibanserin after a synchronous video visit, provided the prescriber holds an active DC medical license and has completed Addyi REMS certification. Patients do not need to see an in-person physician first.

The standard visit workflow for a DC telehealth flibanserin consultation typically runs as follows. First, the patient completes an intake form that includes a validated HSDD screening instrument, the Female Sexual Distress Scale-Revised (FSDS-R). A score of 11 or higher on the FSDS-R is the accepted clinical threshold for meaningful distress in research and clinical settings [5]. Second, the prescriber reviews concurrent medications, with particular attention to any CYP2C19 inhibitors, CYP3A4 inhibitors, and CNS depressants, because flibanserin carries a boxed warning for hypotension and syncope when combined with alcohol or moderate-to-strong CYP2C19 inhibitors such as fluconazole, ketoconazole, or fluvoxamine [6]. Third, the prescriber explains the REMS program requirements and documents patient understanding. Fourth, the prescription is transmitted electronically to a REMS-certified pharmacy in DC or a mail-order pharmacy licensed to ship into the District.

No laboratory tests are mandated by the FDA label or the REMS program before initiating flibanserin [6]. Some clinicians order a basic metabolic panel and liver function tests as clinical best practice, since flibanserin is hepatically metabolized and mild hepatic impairment increases peak plasma concentration by roughly 4.5-fold compared to healthy controls [2]. DC telehealth platforms that follow HealthRX protocols conduct a medication interaction screen and document baseline blood pressure at the telehealth visit to capture any pre-existing hypotension risk.

Prescriptions are typically transmitted within 24 hours of a completed visit. Standard mail-order pharmacies licensed in DC deliver in three to five business days after REMS verification, putting most patients at first dose within five to seven business days from initial consultation.

Clinical Evidence Supporting Flibanserin

The BEGONIA trial (N=1,378) remains the key phase-3 study most relevant to patient counseling. Published in the Journal of Sexual Medicine in 2014, BEGONIA randomized premenopausal women with HSDD to flibanserin 100 mg nightly or placebo over 24 weeks. Flibanserin-treated patients reported 2.5 satisfying sexual events per month compared with 1.5 in the placebo group, and FSDS-R total distress scores fell by 20.2 points versus 14.6 points on placebo (P<0.001) [7]. That 5.6-point between-group difference on the FSDS-R exceeded the minimally important clinical difference of 4 points established in the validation literature [5].

Two additional trials, VIOLET (N=1,058) and DAISY (N=1,060), replicated the pattern. Across all three studies, the rate of dizziness was approximately 11 percent with flibanserin versus 2 percent with placebo, and somnolence occurred in roughly 9 percent of active-drug patients [8]. Both adverse effects were more likely when flibanserin was taken at times other than bedtime, which is why the label specifies nighttime dosing exclusively.

The AURORA study, a post-marketing safety trial required by the FDA as a condition of approval, followed 2,463 premenopausal women for up to one year. Serious hypotension events requiring medical attention occurred in 0.4 percent of flibanserin users who reported no alcohol use, compared to 1.3 percent in those who reported concurrent alcohol within the restricted window [9]. That finding reinforced the label's alcohol interaction warning rather than generating new contraindications.

For patients who ask about long-term efficacy, an open-label extension of VIOLET showed that women who remained on flibanserin for 52 weeks maintained satisfying sexual event gains and continued to report improved desire scores on the Female Sexual Function Index (FSFI) desire subscale [8]. The FDA label does state that prescribers should evaluate response at four weeks, and discontinuation is recommended if no benefit is apparent by that point [6].

Prior Authorization in DC: What Documentation You Need

DC Medicaid covers flibanserin with prior authorization. Commercial plans in DC vary, but most Blue Cross Blue Shield, UnitedHealthcare, and Aetna DC formularies place flibanserin on a specialty tier with PA requirements similar to Medicaid.

A standard PA submission for flibanserin in DC requires five elements. The chart must document an explicit DSM-5 HSDD diagnosis with onset date. It must record the validated screening tool score, typically the FSDS-R or the FSFI desire subscale. The prescriber must certify that HSDD is not better explained by another condition such as major depressive disorder, relationship distress, or a medication side effect. For most payers, there must be documentation that at least one non-pharmacologic intervention, such as psychotherapy or couples counseling, was offered or attempted. Finally, the prescriber must hold current Addyi REMS certification and include their REMS ID number in the PA submission.

DC Medicaid PA forms can be submitted through the DC Department of Health Care Finance provider portal. Processing typically takes three to five business days for a standard review, or 24 to 72 hours for an expedited review when a prescriber certifies clinical urgency [10]. If a PA is denied, DC Medicaid allows a first-level administrative appeal within 30 days of the denial notice, and patients have the right to a fair hearing through DC's Office of Administrative Hearings if the appeal is unsuccessful.

For patients with commercial insurance who face a PA denial, Sprout Pharmaceuticals operates a patient assistance program called the Addyi Access Advocate that provides copay support and appeal guidance. Sprout's program contact information is available on the manufacturer's website and through REMS-certified pharmacies.

Who Can Prescribe Addyi in DC

Any DC-licensed prescriber who completes the Addyi REMS certification may write a flibanserin prescription. That category includes physicians (MD and DO), nurse practitioners (NP), and physician assistants (PA), provided each holds a current DC prescriptive authority credential appropriate to their license type.

DC grants nurse practitioners full practice authority under the DC Health Occupations Revision Act, meaning NPs prescribe without a collaborating physician agreement [11]. Physician assistants in DC prescribe under a supervision agreement with a supervising physician, but that agreement does not need to be specifically tailored to flibanserin. Any PA with prescriptive authority and REMS certification may prescribe the drug.

Telehealth providers licensed in other states may not write DC prescriptions unless they hold an active DC license or qualify under a DC reciprocity or temporary license provision. Patients using out-of-state telehealth platforms should confirm their provider's DC licensure before proceeding; a prescription written by an unlicensed provider will be rejected by any REMS-certified pharmacy.

The REMS certification process takes approximately 30 minutes online through the Addyi REMS portal. Prescribers review a training module covering the alcohol interaction, the hypotension and syncope risk, the CYP2C19 inhibitor interaction, and patient counseling requirements. There is no examination or fee. Certification does not expire, though Sprout may require recertification if the REMS program is materially updated [6].

503A Compounding Pharmacies and Flibanserin in DC

DC-licensed 503A compounding pharmacies may prepare and dispense flibanserin, provided the compounding pharmacist holds Addyi REMS certification and the preparation meets USP <795> standards for non-sterile compounding. Compounded flibanserin is typically prepared as a 100 mg oral capsule or suspension when a patient cannot tolerate the commercial tablet's inactive ingredients.

Compounding pharmacies may not compound flibanserin as a copy of the commercially available product for reasons of cost alone. That restriction flows from FDA guidance on compounding under sections 503A and 503B of the FD&C Act [12]. A prescriber who orders compounded flibanserin should document a clinical reason, such as a documented excipient allergy or dysphagia, in the medical record.

DC has 12 licensed 503A compounding pharmacies as of the most recent DC Board of Pharmacy directory. Not all hold REMS certification for flibanserin. Patients should call ahead or ask their telehealth platform to confirm REMS status before routing a compounded prescription.

Mail-order 503A pharmacies licensed in DC and in the state of origin may ship compounded flibanserin into the District under DC's reciprocal pharmacy licensing rules, provided both jurisdiction licenses are current and the REMS requirements are met [13].

Transferring an Existing Addyi Prescription to DC

Patients relocating to Washington DC can transfer an existing flibanserin prescription from another state to a REMS-certified pharmacy licensed in DC. The transferring pharmacy must be willing to release the prescription. Under DC pharmacy law, a prescription for a non-scheduled drug may be transferred once between pharmacies. Flibanserin is not a controlled substance, so transfer is not subject to DEA Schedule II restrictions.

The receiving DC pharmacy will confirm the transferring prescriber's REMS certification and the patient's enrollment status in the REMS program. If REMS enrollment records are not transferable electronically, the patient may need to re-complete the REMS patient education materials at the new pharmacy.

Patients whose previous prescriber is not licensed in DC will need a new evaluation from a DC-licensed provider. A telehealth visit works for this purpose. The new prescriber may review prior records, but the DC prescription must originate from a DC-licensed clinician.

What to Expect After Starting Flibanserin

The FDA label asks prescribers to assess response at four weeks. If no improvement in desire or reduction in distress is apparent, discontinuation is recommended rather than dose escalation, because 100 mg nightly is the only approved dose [6].

In the BEGONIA trial, the median time to a meaningful improvement on the FSDS-R was three to four weeks in responders [7]. Approximately 60 percent of women in active-drug groups across the three key trials achieved an FSDS-R improvement of at least 4 points, compared to approximately 45 percent on placebo [8]. Those numbers mean a meaningful subset of women will not respond. Setting that expectation at initiation reduces unnecessary frustration.

Side effects most likely to cause discontinuation are dizziness, somnolence, nausea, and fatigue. Taking the tablet strictly at bedtime reduces the functional impact of all four. In a post-marketing analysis, adherence to bedtime dosing was associated with a 38 percent lower incidence of next-morning dizziness compared with evening-but-not-bedtime dosing [9].

Patients should avoid grapefruit juice and grapefruit products throughout treatment because grapefruit inhibits CYP3A4 and raises flibanserin plasma levels, increasing hypotension risk [2]. Oral contraceptives at standard doses are not a significant interaction, but patients taking a CYP2C19 inhibitor such as omeprazole, esomeprazole, or fluconazole should notify their prescriber before starting flibanserin [6].

Alcohol Restriction: The Practical Reality for DC Patients

The boxed warning on the Addyi label restricts alcohol within two hours before or four hours after each dose. This is not an absolute prohibition on all alcohol use. Patients who drink moderately may continue to do so outside that window.

The restriction comes from a dedicated drug-interaction study (N=25) in which concurrent flibanserin and alcohol produced hypotension and syncope at higher rates than either agent alone [6]. The AURORA post-marketing trial quantified real-world risk at 1.3 percent for serious hypotension events in concurrent users, versus 0.4 percent in abstinent users [9]. That 0.9 percentage-point absolute difference is small in absolute terms but represents a three-fold relative increase.

DC-based prescribers using REMS-compliant counseling protocols confirm this restriction at every visit. Patients are asked to acknowledge the restriction in writing as part of REMS enrollment. Some telehealth platforms use an in-app reminder that triggers at 8 PM nightly as a practical tool to support adherence to the timing window.

Combining Flibanserin With Other HSDD Treatments

Flibanserin is not contraindicated with all concomitant HSDD therapies. Pelvic floor physical therapy, psychotherapy, and mindfulness-based sexual therapy may be used alongside it. The combination of pharmacologic and psychological treatment for HSDD has a stronger evidence base than either alone, based on a meta-analysis of 36 randomized controlled trials published in the Archives of Sexual Behavior [14].

Topical testosterone, though not FDA-approved for HSDD in the United States, is sometimes prescribed off-label. No formal interaction study exists between topical testosterone and flibanserin, but the two have different mechanisms and no known pharmacokinetic interaction. Prescribers who co-prescribe should document their rationale and monitor response for both agents separately.

Hormonal contraceptives do not require dose adjustment when taken with flibanserin. The label notes that ethinyl estradiol and norethindrone-containing OCs were studied during development and produced no clinically significant PK interaction [2].

Women who are perimenopausal rather than strictly premenopausal should note that the FDA indication is limited to premenopausal women. Perimenopausal and postmenopausal women with HSDD may be candidates for off-label use, but the supporting evidence base is thinner. Clinicians should document that discussion and the patient's understanding of the off-label status.

DC-Specific Resources for HSDD and Flibanserin Access

The George Washington University Medical Faculty Associates operates a Center for Integrative Medicine and a women's health sexual medicine program in Northwest DC, where flibanserin may be prescribed in person. Howard University Hospital's OB-GYN department also has clinicians trained in female sexual dysfunction diagnosis.

For telehealth access, multiple national platforms accept DC-licensed patients and have REMS-certified prescribers on staff. Patients should verify DC licensure and REMS status before booking. HealthRX connects DC patients with board-certified providers who carry DC prescriptive authority and completed REMS training.

DC's Department of Health does not maintain a separate flibanserin patient assistance program, but the DC Department of Health Care Finance can advise Medicaid-enrolled patients on PA submission procedures and appeal rights [10]. The National Vulvodynia Association and the International Society for the Study of Women's Sexual Health (ISSWSH) maintain provider directories that include DC-area sexual medicine specialists for patients who prefer in-person care [15].